Acute Myeloid Leukemia

	A	B	C	D	E	F	G	H	I	J	K	L
1	info	Title	Acute Myeloid Leukemia (aml) Data Dictionary
2	info	Name	aml_v2.0-approved
3	info	Description	A tabular data dictionary for aml_v2.0-approved can be viewed online at: https://docs.google.com/spreadsheets/d/1_KyfeZNsepIxSU0Nzw5Mi8mk1PiKCWlSBjatw0AECQ0
4	info	Parent Model	pcdc_v2.0
5	info	License	CC BY-NC 4.0
6	info	Documentation	https://commons.cri.uchicago.edu/pcdc/
7
8	RowType	VariableName	DataType	Tier	VariableDescription	VariableCode	PermissibleValue	ValueDescription	ValueCode	ImplementationNotes	SyntacticMappings	SemanticMappings
9
10	domain	demographics
11	table	DataContributorPersonRecord								D4CGNote: One observation/row per a data contributor record of a person.
12	var	submitter_id	string	mandatory						D4CGNote: Submitter-provided identifer
13	var	person_submitter_id	string	mandatory						D4CGNote: Foreign-key reference to a Person record D4CGNote: The person_submitter_id will be provided by D4CG. Data contributors do not need to supply this value.
14	var	honest_broker_subject_id	string	mandatory	Subject identifier assigned by the honest broker.	ncit:C168949
15	var	data_contributor_id	enum	mandatory	An identifier assigned to a data contributor.	ncit:C168950
16	pv						AIEOP	A group from Bologna, Italy, comprised mainly of pediatricians, hematologists, oncologists, surgeons, biologists, nurses and psychologists who are devoted to addressing the problems of hematology, oncology and immunology in the child and adolescent.	ncit:C168887
17	pv						BFM-SG	A study group formed in 1975 by three individuals, Hansjorg Riehm in Berlin (B), Bernhard Kornhuber in Frankfurt (F) and Gunther Schellong in Munster (M), who initiated the first multicenter BFM trial. The BFM treatment concept was based on an intensive chemotherapeutic approach employing eight different drugs which led to a revolutionary increase in the survival of children and adolescents with acute lymphoblastic leukemia.	ncit:C168888
18	pv						CCHE 57357			ConsortiumNote: Children's Cancer Hospital Egpyt 57357
19	pv						COG	An NCI-supported clinical cooperative group formed by the merger of the four national pediatric cancer research organizations: the Children's Cancer Group, the Intergroup Rhabdomyosarcoma Study Group, the National Wilms Tumor Study Group, and the Pediatric Oncology Group. The primary objective of the organization is to conduct clinical trials of new therapies for childhood and adolescent cancer. COG develops and coordinates clinical trials conducted at the 238 member institutions that include cancer centers of all major universities and teaching hospitals throughout the U.S. and Canada, as well as sites in Europe and Australia. COG members include over 5000 cancer researchers.	ncit:C39353
20	pv						DCOG	A collaborating partner in Innovative Therapies for Children with Cancer Consortium (ITCC), a European based consortium to promote the clinical evaluation of new anti-cancer compounds in children with cancer.	ncit:C168889
21	pv						JACLS	A study group in Japan investigating childhood leukemia.	ncit:C168890
22	pv						JPLSG	A study group in Japan investigating pediatric leukemia and lymphoma.	ncit:C168891
23	pv						MRC	A publicly funded organization that is part of United Kingdom Research and Innovation, and is dedicated to improving human health through world-class medical research.	ncit:C168892
24	pv						NOPHO	A collaborative group formed in 1984 with members from Denmark, Finland, Iceland, Lithuania, Norway and Sweden and whose goal was to secure that all Nordic children suffering from leukemia would receive optimal therapy wherever they lived.	ncit:C168893
25	pv						PPLLSG	A collaborative group established in 1974 that had the original goal of implementing unified protocols with standardized diagnostic criteria and therapy regimens for Hodgkin's disease and acute lymphoblastic leukemia. The prospects were widened to include non-Hodgkin's lymphomas and acute myelogenous leukemia in 1983.	ncit:C168894
26	pv						SJCRH	The St. Jude Children's Research Hospital received its NCI designation in 1977 and was awarded status as a comprehensive cancer center by NCI in 2008. Research is focused specifically on childhood cancers, acquired and inherited immunodeficiencies and genetic disorders.	ncit:C39510
27
28
29	domain	demographics
30	table	Subject								D4CGNote: One observation/row per instance of a DataContributorPerson being enrolled on a study
31	var	submitter_id	string	mandatory						D4CGNote: Submitter-provided identifer
32	var	data_contributor_person_record_submitter_id	string	mandatory						D4CGNote: Foreign-key reference to a DataContributorPersonRecord record (by submitter_id)
33	var	consortium	enum	mandatory	A group formed to undertake a venture that is beyond the capabilities of the individual members. Each member of the consortium brings a high level of expertise in a specific area to ensure the successful completion of the project.	ncit:C61538
34	pv						INTERACT	A consortium launched in 2021 as a collaboration between acute myeloid leukemia researchers from Children's Oncology Group, European Pediatric Acute Leukemia, Japan Children's Cancer Group, and St. Jude Children's Research Hospital. To date, INTERACT has identified 18 studies from 10 clinical trials research groups that can be contributed to the data commons, and its statisticians are actively working to harmonize clinical data from more than 6,000 individuals who have had pediatric cancer.	ncit:C192762
35	var	disease_group	enum	mandatory
36	pv						AML
37	var	sex	enum	priority	An arbitrary categorization of individuals based on the assemblage of physical properties related to reproduction, and commonly associated with the designation of such categories as female and male. This designation is based on a combination of observable information from organ inventories, morphological assessments, hormone assessments, genetic testing, observed primary and secondary sex characteristics, menstrual status, and/or obstetric history. Current sex designation may or may not be the same as an individual's sex assigned or reported at birth. IMPORTANT NOTICE: The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.	ncit:C28421
38	pv						Female	A person who belongs to the sex that normally produces ova. The term is used to indicate biological sex distinctions, or cultural gender role distinctions, or both. [The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.]	ncit:C16576
39	pv						Male	A person who belongs to the sex that normally produces sperm. The term is used to indicate biological sex distinctions, cultural gender role distinctions, or both. [The NCI Thesaurus contains biomedical terminologies that NCI does not own or control. This concept contains gender-related content that does not comply with Executive Order 14168.]	ncit:C20197
40	pv						Other	A proper value is applicable but not known.	ncit:C17649
41	pv						Unknown	A proper value is applicable but not known.	ncit:C17998
42	pv						Not Reported	Not provided or available.	ncit:C43234
43	var	race	enum	priority	A geographic ancestral origin category that is assigned to a population group based mainly on physical characteristics that are thought to be distinct and inherent.	ncit:C17049
44	pv						American Indian or Alaska Native	A person having origins in any of the original peoples of North and South America (including Central America), and who maintains tribal affiliation or community attachment. (FDA)	ncit:C41259
45	pv						Asian	A person having origins in any of the original peoples of the Far East, Southeast Asia, or the Indian subcontinent including, for example, Cambodia, China, India, Japan, Korea, Malaysia, Pakistan, the Philippine Islands, Thailand, and Vietnam. (FDA)	ncit:C41260
46	pv						Black or African American	A person having origins in any of the black racial groups of Africa. Terms such as "Haitian" or "Negro" can be used in addition to "Black or African American." (FDA)	ncit:C16352
47	pv						Multiracial	Having ancestors of several or various races.	ncit:C67109
48	pv						Native Hawaiian or Other Pacific Islander	Denotes a person having origins in any of the original peoples of Hawaii, Guam, Samoa, or other Pacific Islands. The term covers particularly people who identify themselves as part-Hawaiian, Native Hawaiian, Guamanian or Chamorro, Carolinian, Samoan, Chuu. (FDA)	ncit:C41219
49	pv						White	Denotes a person with European, Middle Eastern, or North African ancestral origin who identifies, or is identified, as White. (FDA)	ncit:C41261
50	pv						Other	A proper value is applicable but not known.	ncit:C17649
51	pv						Unknown	A proper value is applicable but not known.	ncit:C17998
52	pv						Not Reported	Not provided or available.	ncit:C43234
53	var	ethnicity	enum	priority	A social group characterized by a distinctive social and cultural tradition that is maintained from generation to generation. Members share a common history and origin and a sense of identification with the group. They have similar and distinctive features in their lifestyle habits and shared experiences. They often have a common genetic heritage which may be reflected in their experience of health and disease.	ncit:C16564
54	pv						Hispanic or Latino	A person of Mexican, Puerto Rican, Cuban, Central or South American or other Spanish culture or origin, regardless of race. (NCI)	ncit:C17459
55	pv						Not Hispanic or Latino	A person not of Cuban, Mexican, Puerto Rican, South or Central American, or other Spanish culture or origin, regardless of race.	ncit:C41222
56	pv						Unknown	A proper value is applicable but not known.	ncit:C17998
57	pv						Not Reported	Not provided or available.	ncit:C43234
58
59
60	domain	demographics
61	table	ExternalReference								D4CGNote: One observation/row per ___ when instantiated
62	var	subjects_submitter_id	string	mandatory						D4CGNote: Foreign-key reference to a Subject record (by submitter_id)
63	var	external_links	string	optional
64	var	external_resource_icon_path	string	optional
65	var	external_resource_id	string	optional
66	var	external_resource_name	string	optional
67	var	external_subject_id	string	optional
68	var	external_subject_submitter_id	string	optional
69	var	external_subject_url	string	optional
70
71
72	domain	demographics
73	table	StudyMetadata								D4CGNote: One observation/row per study
74	var	submitter_id	string	mandatory						D4CGNote: Submitter-provided identifer
75	var	subjects_submitter_id	string	mandatory						D4CGNote: Foreign-key reference to a Subject record (by submitter_id)
76	var	study_id	enum	mandatory	A sequence of characters used to identify, name, or characterize the study.	ncit:C83082
77	pv						AAML03P1	The identifier AAML03P1, assigned to a study in an AML clinical trial.	ncit:C168936
78	pv						AAML0531	The identifier AAML0531, assigned to an AML study in a clinical trial.	ncit:C168937
79	pv						AAML1031	The identifier AAML1031, assigned to a study in an AML clinical trial.	ncit:C168938
80	pv						AEIOPAML2002	The identifier AEIOPLAM2002, assigned to a study in an AML clinical trial.	ncit:C168942
81	pv						AIEOPLAM92	The identifier AIEOPLAM92, assigned to a study in an AML clinical trial.	ncit:C173254
82	pv						AML-BFM Registry2012	The identifier AMLBFMRegistry2012, assigned to a study in an AML clinical trial.	ncit:C173251
83	pv						AML-BFM Registry2017	The identifier AMLBFMRegistry2017, assigned to a study in an AML clinical trial.	ncit:C182031
84	pv						AML-BFM1998	The identifier AMLBFM1998, assigned to a study in an AML clinical trial.	ncit:C182032
85	pv						AML-BFM2004	The identifier AMLBFM2004, assigned to a study in an AML clinical trial.	ncit:C168939
86	pv						AML-BFM2004 Interim
87	pv						AML-BFM2012	The identifier AMLBFM2012, assigned to a study in an AML clinical trial.	ncit:C173250
88	pv						AML-BFM2019
89	pv						AML-BFM2020
90	pv						AML-BFM83/87
91	pv						AML-BFM87/93
92	pv						AML-BFM93
93	pv						AML-BFM98
94	pv						AML-BFM98 Interim 2003
95	pv						APL
96	pv						DBAML01	The identifier DBAML01, assigned to a study in an AML clinical trial.	ncit:C168944
97	pv						Egypt57357-AML
98	pv						JACLSAML99	The identifier JACLSAML99, assigned to a study in an AML clinical trial.	ncit:C168943
99	pv						JPLSGAML05	The identifier JPLSGAML05, assigned to a study in an AML clinical trial.	ncit:C168941
100	pv						ML-DS-2006